Skip to main content

Skleo Health GmbH

Category: AI in Healthcare

An AI-powered platform providing accessible and medically-validated eye disease screenings in non-clinical settings like pharmacies and opticians to prevent avoidable blindness. Skleo Health GmbH was founded in 2024. The company is led by Vincent Fabien Vogl. Based in Düsseldorf, North Rhine-Westphalia, Germany. Team size: 11-50. Total funding raised: €3 million. Latest round: Seed, €3.0M, 2025-07, led by Sanoptis. Key investors include Sanoptis, Antler.

Founded
2024
Headquarters
Düsseldorf, North Rhine-Westphalia, Germany
Team size
11-50
Total funding
€3 million

Value proposition

Enables rapid, affordable, and convenient detection of retinal diseases using accessible hardware and a cloud-based, dual-validation (AI + human) platform, democratizing access to sight-saving diagnostics without long wait times for specialist appointments.

Products and solutions

Skleo Eye Screening Platform: A comprehensive service that combines a rapid, six-minute eye screening performed at partner locations (e.g., pharmacies, opticians) with a dual-step analysis using CE-certified AI and review by a specialist eye doctor.

Unique value

Combines low-cost, smartphone-based fundus imaging with a proprietary, CE-certified AI for initial analysis, followed by validation from a remote ophthalmologist. This hybrid model allows for rapid, scalable, and medically reliable screenings outside of traditional clinics.

Target customer

B2B partners such as pharmacy chains, opticians, retail stores, and corporations who wish to offer on-site preventive health screenings to their customers and employees. The ultimate beneficiaries are patients, particularly those with chronic conditions like diabetes.

Industries served

Healthcare, Telemedicine, Preventive Medicine, Retail Health

Technology advantage

CE-certified medical device software compliant with EU MDR regulations. The platform provides a seamless, two-step validation process (AI followed by a human specialist) and is built for high scalability in both retail and clinical settings.

How they differentiate

Skleo focuses on extreme accessibility by partnering with pharmacies, opticians, and retailers. Its model emphasizes a rapid, low-cost screening integrated into everyday locations, combined with a dual-validation process (AI and human specialist) to ensure quality and compliance with European standards.

Main competitors

Eyenuk, RetinaLyze, Toku Eyes (AiVisionHealth)

Key partnerships

Sanoptis (strategic investor and one of Europe's leading ophthalmology services providers), Antler (early-stage VC), A nationwide network of pharmacies, opticians, and retail partners across Germany.

Notable customers

Screening services are offered through a growing network of partners including pharmacies, opticians, and retail stores across Germany.

Major milestones

Founded in March 2024., Secured €3 million in a seed funding round in July 2024., Expanded operations to 50 of the largest cities in Germany within four months of launch., Achieved CE certification for its AI medical device software.

Growth metrics

Launched in March 2024 and expanded to 50 German cities, screening over 11,000 people by July 2024. Identified over 3,000 cases with clinically relevant findings. The company aims to reach a capacity of 30,000 screenings per month.

Market positioning

An emerging, highly accessible, and affordable solution for the German market, targeting mass preventive screening through non-traditional healthcare partners.

Geographic focus

Germany, with planned expansion across Europe.

Patents and IP

Proprietary AI algorithms are protected as trade secrets; no public patents found.

About Vincent Fabien Vogl

Vincent Fabien Vogl is a seasoned professional with a strong background in both engineering and business. He holds an MBA from Collège des Ingénieurs and a Master's degree in Mechanical Engineering from the Technical University of Munich. His career began at The Boston Consulting Group (BCG), where he worked as a consultant. He then transitioned to Air Liquide, where he held several leadership roles, including Head of Business Development & Strategy for Home Healthcare. In March 2024, he co-founded Skleo Health, where he currently serves as CEO.

Official website: